303 related articles for article (PubMed ID: 25333305)
1. Sclerostin: recent advances and clinical implications.
Honasoge M; Rao AD; Rao SD
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
[TBL] [Abstract][Full Text] [Related]
2. Targeting sclerostin as potential treatment of osteoporosis.
Papapoulos SE
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
[TBL] [Abstract][Full Text] [Related]
3. Activating the unfolded protein response in osteocytes causes hyperostosis consistent with craniodiaphyseal dysplasia.
Chan WCW; Tsang KY; Cheng YW; Ng VCW; Chik H; Tan ZJ; Boot-Handford R; Boyde A; Cheung KMC; Cheah KSE; Chan D
Hum Mol Genet; 2017 Dec; 26(23):4572-4587. PubMed ID: 28973168
[TBL] [Abstract][Full Text] [Related]
4. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck.
Power J; Doube M; van Bezooijen RL; Loveridge N; Reeve J
Bone; 2012 May; 50(5):1107-14. PubMed ID: 22353552
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin: current knowledge and future perspectives.
Moester MJ; Papapoulos SE; Löwik CW; van Bezooijen RL
Calcif Tissue Int; 2010 Aug; 87(2):99-107. PubMed ID: 20473488
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin, an osteocytes-derived bone-forming inhibitor.
Włodarski KH; Galus R; Brodzikowska A; Włodarski PK
Pol Orthop Traumatol; 2013 Jul; 78():151-4. PubMed ID: 23820854
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
8. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.
Rossini M; Gatti D; Adami S
Calcif Tissue Int; 2013 Aug; 93(2):121-32. PubMed ID: 23748710
[TBL] [Abstract][Full Text] [Related]
9. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
11. NMR structure of the Wnt modulator protein Sclerostin.
Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD
Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin deficiency in humans.
van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
[TBL] [Abstract][Full Text] [Related]
13. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
16. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
[TBL] [Abstract][Full Text] [Related]
17. Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge.
Anastasilakis AD; Polyzos SA; Toulis KA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):383-8. PubMed ID: 21897222
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
19. Targeting WNT signaling in the treatment of osteoporosis.
Baron R; Gori F
Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
[TBL] [Abstract][Full Text] [Related]
20. Does osteocytic SOST suppression mediate PTH bone anabolism?
Kramer I; Keller H; Leupin O; Kneissel M
Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]